Table 1 Clinicopathological and molecular characteristics of study patients
Category | Group A | Group B | Group C |
|---|---|---|---|
No. Patient | 34 | 35 | 22 |
Age: median (range) | 67.3 (43–85) | 69.9 (45–92) | 67.1 (55–81) |
Gender: female N (%) | 22 (64.7%) | 17 (48.6%) | 10 (45.5%) |
Race/ethnicity: N (%) | |||
 Non-Hispanic White | 16 (47.1%) | 32 (91.4%) | 17 (77.3%) |
 Hispanic | 1 (2.9%) | 1 (2.9%) | 4 (18.2%) |
 Asian | 17 (50.0%) | 2 (5.7%) | 1 (4.5%) |
Histology: N (%) | |||
 LUAD | 33 (97.1%) | 25 (74.4%) | 14 (63.6%) |
 LUSC | 1 (2.9%) | 10 (28.5%) | 4 (18.2%) |
 NSCLC-NOS | 0 (0%) | 0 (0%) | 4 (18.2%) |
Driver oncogene mutations: | 34 (100%) | 0 (0%) | 7 (31.8%) |
 EGFR mutations | 24 (70.6%) | 0 (0%) | 3 (13.6%) |
 ALK fusions | 3 (8.8%) | 0 (0%) | 2 (9.1%) |
 HER2 alterations | 3 (8.8%) | 0 (0%) | 1 (4.5%) |
 MET alterations | 3 (8.8%) | 0 (0%) | 1 (4.5%) |
 RET fusions | 1 (2.9%) | 0 (0%) | 0 (0%) |